Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS) of 16.5 months vs. 9.2 months for sunitinib alone (HR=0.50; 95% CI 0.39–0.65; p<0.0001) and a 46% objective response rate vs. 26% on sunitinib monotherapy (p<0.0001). [1]
“It is a historic day for Cogent Biosciences and the GIST patient community,” CEO Andrew Robbins said, adding that the bezuclastinib combination “is poised to become the new standard of care” in second‑line GIST. [2]
By the numbers (PEAK top‑line)
- Primary endpoint (PFS): 16.5 mo vs. 9.2 mo; risk of progression/death cut by 50%. [3]
- Objective response rate: 46% vs. 26% (p<0.0001). [4]
- Safety: Combination generally well tolerated with no unique risks vs. known sunitinib profile; most common Grade ≥3 AEs included hypertension (29.4% vs. 27.4%), neutropenia (15.2% vs. 15.4%), ALT/AST increase (10.8% vs. 1.4%), anemia (9.3% vs. 4.8%), diarrhea (7.8% vs. 7.2%). ALT/AST elevations led to 12.7% dose reductions; no Grade 4 transaminase elevations reported. Overall survival data are immature. [5]
- Scale of study:n=413 randomized (204 combination; 209 monotherapy); demographics and regional split consistent across arms. [6]
- Company claim: This is the first positive Phase 3 trial in second‑line GIST in over 20 years. [7]
Why it matters
Second‑line GIST has long relied on sunitinib, but resistance driven by a spectrum of KIT mutations (exons 9, 11, 13, 14, 17, 18) limits durability. Bezuclastinib is a selective KIT inhibitor designed to cover the resistant mutation landscape; paired with sunitinib, the regimen aims to broaden mutational coverage and extend disease control. Slide materials from today’s investor webcast highlight the combination’s intended coverage across those key KIT exons. [8]
Stock reaction (intraday)
As of 14:57 UTC on Nov. 10, COGT traded around $31.91, up roughly 115% from the prior close, after opening at $32.73 and trading as high as $40.62 on heavy volume. (Change: +$17.09; intraday volume ~8.75M).
What’s next on the regulatory & clinical timeline
- PEAK (GIST): Cogent plans to submit an NDA in 1H 2026 and present full data at a scientific conference in 1H 2026. [9]
- Non‑advanced systemic mastocytosis (NonAdvSM): The SUMMIT pivotal trial previously met all endpoints; the FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM and smoldering SM on Oct. 20, 2025. Cogent says it remains on track to file an NDA by year‑end 2025. [10]
- Advanced SM (AdvSM):APEX top‑line data are expected in December 2025. [11]
- Near‑term events: Company hosted its 8:00 a.m. ET webcast today; an SEC Form 8‑K with the slide deck and detailed top‑line metrics was filed this morning. [12]
Market opportunity & commercial outlook
In its 8‑K, Cogent estimates a global annual market opportunity of >$4B for bezuclastinib + sunitinib in second‑line GIST, ~$3B for NonAdvSM, and ~$500M for AdvSM. The company also projects the mean duration of treatment for the PEAK combination to exceed 19 months, based on ongoing‑treatment patterns observed at cutoff. (These are company estimates and projections.) [13]
Expert & community commentary from today
The company’s release includes a comment from MD Anderson’s Dr. Neeta Somaiah calling the results “truly transformative and practice‑changing,” and a statement from The Life Raft Group highlighting the long wait for a more effective second‑line option in GIST. (Brief quotes; see full text in source.) [14]
Context: how we got here (background for readers)
- SUMMIT (NonAdvSM): Top‑line (July 2025) showed statistically significant improvements across all primary and key secondary endpoints, underpinning the Breakthrough Therapy decision. Detailed data are slated for ASH 2025 with two oral presentations. [15]
- Corporate readiness: Cogent has been building toward potential commercialization, including an investor webcast deck posted today that outlines trial design, patient demographics, and efficacy curves for PEAK. [16]
Key takeaways for Nov. 10, 2025
- PEAK succeeds: Strong PFS and ORR advantages vs. sunitinib alone; safety manageable with no new combo‑specific risks. [17]
- Regulatory path: GIST NDA 1H 2026; NonAdvSM NDA YE 2025 (with Breakthrough status). [18]
- Shares surge: COGT up ~115% intraday; high $40.62; heavy volume.
Editor’s note: This article covers all Cogent Biosciences news items dated November 10, 2025, centered on the PEAK Phase 3 GIST readout, the related SEC 8‑K, and the market reaction. For source materials, see the Cogent press release (GlobeNewswire), the Form 8‑K, and real‑time market coverage cited above. [19]
This content is for informational purposes only and is not investment advice.
References
1. www.globenewswire.com, 2. www.globenewswire.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. www.sec.gov, 6. www.marketscreener.com, 7. www.globenewswire.com, 8. www.marketscreener.com, 9. www.globenewswire.com, 10. www.globenewswire.com, 11. www.globenewswire.com, 12. www.sec.gov, 13. www.sec.gov, 14. www.globenewswire.com, 15. www.fiercebiotech.com, 16. www.marketscreener.com, 17. www.globenewswire.com, 18. www.globenewswire.com, 19. www.globenewswire.com
![Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]](https://ts2.tech/wp-content/uploads/2025/11/Intellia-Therapeutics-480x384.jpg "Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]")
